Use of Neuregulin to Treat Peripheral Nerve Injury

1 . A composition comprising an effective amount of a neuregulin to prevent or treat a peripheral nerve injury in a subject at risk of incurring a peripheral nerve injury.

2 . The composition of claim 1 , wherein the peripheral nerve is a sciatic nerve.

3 . The composition of claim 1 , wherein the peripheral nerve is a cavernous nerve.

4 . The composition of claim 1 , wherein the peripheral nerve injury results in erectile dysfunction.

5 . The composition of claim 1 , wherein the risk is due to a surgical procedure.

6 . The composition of claim 5 , wherein the surgical procedure is a tissue dissection or a tumor resection.

7 . The composition of claim 6 , wherein the tissue or tumor is a cancer.

8 . The composition of claim 7 , wherein the cancer is a solid cancer.

9 . The composition of claim 7 or 8 , wherein the cancer is a prostate or a breast cancer.

10 . The composition of claim 5 , wherein the surgical procedure is a pelvic, abdominal, or colorectal surgery.

11 . The composition of claim 5 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

12 . The composition of claim 5 , wherein the peripheral nerve is a sciatic nerve.

12 . The composition of claim 5 , wherein the peripheral nerve is a cavernous nerve.

13 . The composition of claim 12 , wherein the peripheral nerve injury results in erectile dysfunction.

14 . The composition of claim 1 , wherein the risk is due to a delivery of an infant.

15 . The composition of claim 14 , wherein the delivery comprises a medical treatment or a surgical procedure.

16 . The composition of claim 15 , wherein the medical treatment is induction of labor.

17 . The composition of claim 15 , wherein the surgical procedure is a caesarian section.

18 . The composition of claim 14 or 15 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

19 . The composition of claim 18 , wherein the peripheral nerve is a sciatic nerve.

20 . The composition of claim 18 , wherein the peripheral nerve is a cavernous nerve.

21 . The composition of claim 1 , wherein the risk is due to a traumatic accident.

22 . The composition of claim 21 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

23 . The composition of claim 22 , wherein the peripheral nerve is a sciatic nerve.

24 . The composition of claim 22 , wherein the peripheral nerve is a cavernous nerve.

25 . The composition of claim 24 , wherein the peripheral nerve injury results in erectile dysfunction.

26 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is suitable for administration prior to incurring the peripheral nerve injury.

27 . The composition of claim 26 , wherein the composition is not administered after incurring the peripheral nerve injury.

28 . The composition of claim 26 , wherein the composition is administered according to a discontinuous dosing regimen.

29 . The composition of claim 28 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

30 . The composition of claim 29 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

31 . The composition of claim 29 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

32 . The composition of claim 28 , 29 , 30 or 31 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

33 . The composition of claim 29 , wherein the specified interval is at least once per week.

34 . The composition of claim 28 , 29 , or 33 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

35 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is suitable for administration in the course of incurring the peripheral nerve injury.

36 . The composition of claim 35 , wherein the composition is not administered after incurring the peripheral nerve injury.

37 . The composition of claim 35 , wherein the composition is administered according to a discontinuous dosing regimen.

38 . The composition of claim 37 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

39 . The composition of claim 38 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

40 . The composition of claim 38 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

41 . The composition of claim 37 , 38 , 39 , or 40 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

42 . The composition of claim 38 , wherein the specified interval is at least once per week.

43 . The composition of claim 37 , 38 , or 42 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

44 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is suitable for administration prior to and in the course of incurring the peripheral nerve injury.

45 . The composition of claim 44 , wherein the composition is not administered after incurring the peripheral nerve injury.

46 . The composition of claim 44 , wherein the composition is administered according to a discontinuous dosing regimen.

47 . The composition of claim 46 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

48 . The composition of claim 47 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

49 . The composition of claim 47 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

50 . The composition of claim 46 , 47 , 48 , or 49 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

51 . The composition of claim 47 , wherein the specified interval is at least once per week.

52 . The composition of claim 46 , 47 , or 51 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

53 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is suitable for administration prior to, in the course of, and after incurring the peripheral nerve injury.

54 . The composition of claim 53 , wherein the composition is administered according to a discontinuous dosing regimen.

55 . The composition of claim 53 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

56 . The composition of claim 55 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

57 . The composition of claim 55 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

58 . The composition of claim 54 , 55 , 56 , or 57 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

59 . The composition of claim 55 , wherein the specified interval is at least once per week.

60 . The composition of claim 54 , 55 , or 59 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

61 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is administered after incurring the peripheral nerve injury according to a discontinuous dosing regimen.

62 . The composition of claim 61 , wherein the discontinuous dosing regimen comprising administering the composition at specified intervals.

63 . The composition of claim 62 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

64 . The composition of claim 62 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

65 . The composition of claim 61 , 62 , 63 , or 64 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

66 . The composition of claim 62 , wherein the specified interval is at least once per week.

67 . The composition of claim 61 , 62 , or 66 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

68 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the composition is not administered after incurring the peripheral nerve injury.

69 . The composition of any one of claims 1 , 5 , 14 , and 21 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

70 . The composition of claim 69 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

71 . The composition of claim 70 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

72 . The composition of claim 71 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

73 . The composition of claim 72 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

74 . The composition of claim 73 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

75 . The composition of claim 74 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

76 . The composition of claim 75 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

77 . The composition of claim 76 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

78 . The composition of claim 26 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

79 . The composition of claim 78 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

80 . The composition of claim 79 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

81 . The composition of claim 80 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

82 . The composition of claim 81 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

83 . The composition of claim 82 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

84 . The composition of claim 83 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

85 . The composition of claim 84 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

86 . The composition of claim 85 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

87 . The composition of claim 35 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

88 . The composition of claim 87 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

89 . The composition of claim 88 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

90 . The composition of claim 89 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

91 . The composition of claim 90 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

92 . The composition of claim 91 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

93 . The composition of claim 92 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

94 . The composition of claim 93 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

95 . The composition of claim 94 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

96 . The composition of claim 44 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

97 . The composition of claim 96 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

98 . The composition of claim 97 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

99 . The composition of claim 98 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

100 . The composition of claim 99 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

101 . The composition of claim 100 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

102 . The composition of claim 101 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

103 . The composition of claim 102 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

104 . The composition of claim 103 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

105 . The composition of claim 53 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

106 . The composition of claim 105 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

107 . The composition of claim 106 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

108 . The composition of claim 107 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

109 . The composition of claim 108 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

110 . The composition of claim 109 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

111 . The composition of claim 110 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

112 . The composition of claim 111 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

113 . The composition of claim 112 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

114 . The composition of claim 61 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

115 . The composition of claim 114 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

116 . The composition of claim 115 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

117 . The composition of claim 116 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

118 . The composition of claim 117 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

119 . The composition of claim 118 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

120 . The composition of claim 119 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

121 . The composition of claim 120 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

122 . The composition of claim 121 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

123 . A composition comprising an effective amount of a neuregulin to prevent or treat a peripheral nerve injury in a subject having an existing peripheral nerve injury.

124 . The composition of claim 123 , wherein the peripheral nerve is a sciatic nerve.

125 . The composition of claim 123 , wherein the peripheral nerve is a cavernous nerve.

126 . The composition of claim 123 , wherein the peripheral nerve injury results in erectile dysfunction.

127 . The composition of claim 123 , wherein the injury is due to a surgical procedure.

128 . The composition of claim 127 , wherein the surgical procedure is a tissue dissection or a tumor resection.

129 . The composition of claim 128 , wherein the tissue or tumor is a cancer.

130 . The composition of claim 129 , wherein the cancer is a solid cancer.

131 . The composition of claim 128 or 129 , wherein the cancer is a prostate or a breast cancer.

132 . The composition of claim 127 , wherein the surgical procedure is a pelvic, abdominal, or colorectal surgery.

133 . The composition of claim 127 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

134 . The composition of claim 127 , wherein the peripheral nerve is a sciatic nerve.

135 . The composition of claim 127 , wherein the peripheral nerve is a cavernous nerve.

136 . The composition of claim 135 , wherein the peripheral nerve injury results in erectile dysfunction.

137 . The composition of claim 123 , wherein the injury is due to a delivery of an infant.

138 . The composition of claim 137 , wherein the delivery comprises a medical treatment or a surgical procedure.

139 . The composition of claim 138 , wherein the medical treatment is induction of labor.

140 . The composition of claim 138 , wherein the surgical procedure is a caesarian section.

141 . The composition of claim 137 or 138 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

142 . The composition of claim 141 , wherein the peripheral nerve is a sciatic nerve.

143 . The composition of claim 141 , wherein the peripheral nerve is a cavernous nerve.

144 . The composition of claim 123 , wherein the injury is due to a traumatic accident.

145 . The composition of claim 144 , wherein the peripheral nerve injury is a nerve transection, a nerve crush, or a nerve demyelination.

146 . The composition of claim 145 , wherein the peripheral nerve is a sciatic nerve.

147 . The composition of claim 145 , wherein the peripheral nerve is a cavernous nerve.

148 . The composition of claim 147 , wherein the peripheral nerve injury results in erectile dysfunction.

149 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is suitable for administration prior to incurring the peripheral nerve injury.

150 . The composition of claim 149 , wherein the composition is not administered after incurring the peripheral nerve injury.

151 . The composition of claim 149 , wherein the composition is administered according to a discontinuous dosing regimen.

152 . The composition of claim 151 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

153 . The composition of claim 152 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

154 . The composition of claim 152 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

155 . The composition of claim 151 , 152 , 153 , or 154 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

156 . The composition of claim 152 , wherein the specified interval is at least once per week.

157 . The composition of claim 151 , 152 , or 156 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

158 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is suitable for administration in the course of incurring the peripheral nerve injury.

159 . The composition of claim 158 , wherein the composition is not administered after incurring the peripheral nerve injury.

160 . The composition of claim 158 , wherein the composition is administered according to a discontinuous dosing regimen.

161 . The composition of claim 160 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

162 . The composition of claim 161 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

163 . The composition of claim 161 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

164 . The composition of claim 160 , 161 , 162 , or 163 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

165 . The composition of claim 161 , wherein the specified interval is at least once per week.

166 . The composition of claim 160 , 161 , or 165 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

167 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is suitable for administration prior to and in the course of incurring the peripheral nerve injury.

168 . The composition of claim 167 , wherein the composition is not administered after incurring the peripheral nerve injury.

169 . The composition of claim 167 , wherein the composition is administered according to a discontinuous dosing regimen.

170 . The composition of claim 169 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

171 . The composition of claim 170 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

172 . The composition of claim 170 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

173 . The composition of claim 169 , 170 , 171 , or 172 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

174 . The composition of claim 170 , wherein the specified interval is at least once per week.

175 . The composition of claim 169 , 170 , or 174 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

176 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is suitable for administration prior to, in the course of, and after incurring the peripheral nerve injury.

177 . The composition of claim 176 , wherein the composition is administered according to a discontinuous dosing regimen.

178 . The composition of claim 177 , wherein the discontinuous dosing regimen comprises administering the composition at specified intervals.

179 . The composition of claim 178 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

180 . The composition of claim 178 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

181 . The composition of claim 177 , 178 , 179 , or 180 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

182 . The composition of claim 178 , wherein the specified interval is at least once per week.

183 . The composition of claim 177 , 178 , or 182 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

184 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is administered after incurring the peripheral nerve injury according to a discontinuous dosing regimen.

185 . The composition of claim 184 , wherein the discontinuous dosing regimen comprising administering the composition at specified intervals.

186 . The composition of claim 185 , wherein the specified intervals are selected from the group consisting of every 24 hours, every 48 hours, and every 72 hours.

187 . The composition of claim 185 , wherein the specified intervals are selected from the group consisting of at least every 24 hours, at least every 48 hours, and at least every 72 hours.

188 . The composition of claim 184 , 185 , 186 , or 187 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, and about 12 weeks.

189 . The composition of claim 185 , wherein the specified interval is at least once per week.

190 . The composition of claim 184 , 185 , or 189 , wherein the discontinuous dosing regimen continues for a period of time selected from the group consisting of about 1 month, about 2 months, or about 3 months.

191 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the composition is not administered after incurring the peripheral nerve injury.

192 . The composition of any one of claims 123 , 127 , 137 , and 144 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

193 . The composition of claim 192 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

194 . The composition of claim 193 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

195 . The composition of claim 194 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

196 . The composition of claim 195 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

197 . The composition of claim 196 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

198 . The composition of claim 197 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

199 . The composition of claim 198 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

200 . The composition of claim 199 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

201 . The composition of claim 149 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

202 . The composition of claim 201 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

203 . The composition of claim 202 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

204 . The composition of claim 203 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

205 . The composition of claim 204 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

206 . The composition of claim 205 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

207 . The composition of claim 206 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

208 . The composition of claim 207 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

209 . The composition of claim 208 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

210 . The composition of claim 158 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

211 . The composition of claim 210 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

212 . The composition of claim 211 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

213 . The composition of claim 212 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

214 . The composition of claim 213 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

215 . The composition of claim 214 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

216 . The composition of claim 215 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

217 . The composition of claim 216 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

218 . The composition of claim 217 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

219 . The composition of claim 167 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

220 . The composition of claim 219 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

221 . The composition of claim 220 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

222 . The composition of claim 221 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

223 . The composition of claim 222 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

224 . The composition of claim 223 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

225 . The composition of claim 224 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

226 . The composition of claim 225 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

227 . The composition of claim 226 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

228 . The composition of claim 176 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

229 . The composition of claim 228 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

230 . The composition of claim 229 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

231 . The composition of claim 230 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

232 . The composition of claim 231 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

233 . The composition of claim 232 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

234 . The composition of claim 233 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

235 . The composition of claim 234 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

236 . The composition of claim 235 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.

237 . The composition of claim 184 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 5 mg/kg of body weight.

238 . The composition of claim 237 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 2.5 mg/kg of body weight.

239 . The composition of claim 238 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 1.5 mg/kg of body weight.

240 . The composition of claim 239 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.7 mg/kg of body weight.

241 . The composition of claim 240 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.5 mg/kg of body weight.

242 . The composition of claim 241 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.3 mg/kg of body weight.

243 . The composition of claim 242 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.1 mg/kg of body weight.

244 . The composition of claim 243 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.05 mg/kg of body weight.

245 . The composition of claim 244 , wherein the effective amount of neuregulin is between about 0.001 mg/kg of body weight to about 0.02 mg/kg of body weight.